Peter Blume-Jensen, Acrivon Therapeutics CEO
June 29, 2021 08:00 AM EDTUpdated 10:31 AM
Startups
Deals

Can a small band of bio­phar­ma play­ers suc­ceed where Eli Lil­ly failed? They’re tak­ing a shot

John Carroll

Editor & Founder

Eli Lil­ly didn’t try to spin any­thing about the mid-stage da­ta they got on their CHK1/CHK2 drug prex­as­ert­ib for ovar­i­an can­cer pa­tients. The drug failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times